Skip to main content

Table 1 Baseline VCA-IgA distribution in 18,286 non-nasopharyngeal carcinoma (NPC) participants by age and sex

From: Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein–Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study

Sex Age (years) No. of participants VCA-IgA [cases (%)] χ2 P
1:5 1:10 1:20 ≥1:40
Male 30–39 3063 2861 (93.4) 108 (3.5) 69 (2.3) 16 (0.5) 9 (0.3)   
40–49 2196 2022 (92.1) 68 (3.1) 76 (3.5) 23 (1.0) 7 (0.3) 11.844 0.001
50–59 1740 1584 (91.0) 73 (4.2) 57 (3.3) 16 (0.9) 10 (0.6)   
Female 30–39 5541 5225 (94.3) 139 (2.5) 129 (2.3) 27 (0.5) 21 (0.4)   
40–49 3070 2855 (93.0) 93 (3.0) 83 (2.7) 24 (0.8) 15 (0.5) 15.475 0.000
50–59 2676 2463 (92.0) 96 (3.6) 71 (2.7) 30 (1.1) 16 (0.6)   
  1. VCA-IgA immunoglobulin A (IgA) antibodies against viral capsid antigen of Epstein–Barr virus (EBV)